Form 4: TG Therapeutics Director Daniel Hume Reports Changes in Beneficial Ownership

Director Daniel Hume reports acquisition of 22,250 shares of TG Therapeutics common stock through a restricted share grant.

Summary

• On June 19, 2024, Daniel Hume, a director of TG Therapeutics, acquired 22,250 shares of common stock.
• These shares were acquired through a grant of restricted shares.
• The restricted shares will vest on June 14, 2025.
• Following the transaction, Hume beneficially owns 240,489 shares of TG Therapeutics common stock, including restricted shares vesting over various time periods.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of a stock transaction by a company director. The acquisition of shares could be seen as slightly positive, but it's not a major event.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers regarding the company's stock.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's investment in the company.

Key Dates